Evidence map›Paper›PMID 36059698›Full record

ArticleFrontiers in oncology2022

Machine learning-featured Secretogranin V is a circulating diagnostic biomarker for pancreatic adenocarcinomas associated with adipopenia.

Yunju Jo, Min-Kyung Yeo, Tam Dao, Jeongho Kwon, Hyon-Seung Yi, Dongryeol Ryu

Abstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yunju JoDepartment of Molecular Cell Biology, Sungkyunkwan University (SKKU) School of Medicine, Suwon, South Korea.
Min-Kyung YeoDepartment of Pathology, Chungnam National University School of Medicine, Daejeon, South Korea.
Tam DaoDepartment of Molecular Cell Biology, Sungkyunkwan University (SKKU) School of Medicine, Suwon, South Korea.
Jeongho KwonDepartment of Molecular Cell Biology, Sungkyunkwan University (SKKU) School of Medicine, Suwon, South Korea.
Hyon-Seung YiDepartment of Medical Science, Chungnam National University School of Medicine, Daejeon, South Korea.
Dongryeol RyuDepartment of Molecular Cell Biology, Sungkyunkwan University (SKKU) School of Medicine, Suwon, South Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pancreatic cancer is one of the most fatal malignancies of the gastrointestinal cancer, with a challenging early diagnosis due to lack of distinctive symptoms and specific biomarkers. The exact etiology of pancreatic cancer is unknown, making the development of reliable biomarkers difficult. The accumulation of patient-derived omics data along with technological advances in artificial intelligence is giving way to a new era in the discovery of suitable biomarkers. Methods: We performed machine learning (ML)-based modeling using four independent transcriptomic datasets, including GSE16515, GSE62165, GSE71729, and the pancreatic adenocarcinoma (PAC) dataset of the Cancer Genome Atlas. To find candidates for circulating biomarkers, we exported expression profiles of 1,703 genes encoding secretory proteins. Integrating three transcriptomic datasets into either a training or test set, ML-based modeling distinguishing PAC from normal was carried out. Another ML-model classifying long-lived and short-lived patients with PAC was also built to select prognosis-associated features. Finally, circulating level of SCG5 in the plasma was determined from the independent cohort (non-tumor = 25 and pancreatic cancer = 25). We also investigated the impact of SCG5 on adipocyte biology using recombinant protein. Results: Three distinctive ML-classifiers selected 29-, 64- and 18-featured genes, recognizing the only common gene, Conclusion: Circulating SCG5, which may be associated with adipopenia, is a promising diagnostic biomarker for PAC.

Indexed as

adipopeniabiomarkercachexiadiagnosismachine learningpancreatic adenocarcinomapancreatic cancerprognosis

Identifiers

PMID36059698
PMCPMC9428794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.